Denali Therapeutics Inc (NQ: DNLI )

54.30 USD +0.33 (+0.61%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 7, 2021 Add to My Watchlist

Price and Volume

Volume	310,208
Open	54.34
Bid (Size)	54.30 (25)
Ask (Size)	54.37 (1)
Prev. Close	53.97
Today's Range	53.48 - 55.69
52wk Range	21.41 - 93.94
Shares Outstanding	121,192,210
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights

May 03, 2021

Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease

May 01, 2021

Performance

YTD	-23.37%	-23.37%
1 Month	+2.47%	+2.47%
3 Month	-29.44%	-29.44%
6 Month	-2.71%	-2.71%
1 Year	+127.29%	+127.29%

More News

Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer

March 30, 2021

Denali Therapeutics Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

March 11, 2021

Tessera Therapeutics Strengthens Leadership Team to Advance ‘Gene Writing’ Platform & Accelerate Therapeutic Development

April 07, 2021

Denali-Biogen Parkinson's Disease Candidate Shows Reductions In Biomarkers; Late Study To Begin By 2021 End

May 03, 2021

Denali Therapeutics Reports Full Year 2020 Financial Results and Business Highlights

February 25, 2021

Denali Therapeutics Moves Up In Market Cap Rank, Passing Sealed Air

April 27, 2021

DNLI Makes Notable Cross Below Critical Moving Average

April 09, 2021

We Did The Math PTH Can Go To $200

April 05, 2021

Stock Upgrades: Denali Therapeutics Shows Rising Relative Strength

April 22, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.